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Abstract Purpose: We performed
a survey on acute heart failure (AHF)
in nine countries in four continents.
We aimed to describe characteristics
and management of AHF among
various countries, to compare patients
with de novo AHF versus patients
with a pre-existing episode of AHF,
and to describe subpopulations hos-
pitalized in intensive care unit (ICU)
versus cardiac care unit (CCU) versus
ward. Methods and results: Data
from 4,953 patients with AHF were
collected via questionnaire from 666
hospitals. Clinical presentation inclu-
ded decompensated congestive HF
(38.6%), pulmonary oedema (36.7%)
and cardiogenic shock (11.7%).
Patients with de novo episode of AHF
(36.2%) were younger, had less
comorbidities and lower blood pres-
sure despite greater left ventricular
ejection fraction (LVEF) and were
more often admitted to ICU.Overall,
intravenous (IV) diuretics were given
in 89.7%, vasodilators in 41.1%, and
inotropic agents (dobutamine, dopa-
mine, adrenaline, noradrenaline and
levosimendan) in 39% of cases.
Overall hospital death rate was 12%,
the majority due to cardiogenic shock
(43%). More patients with de novo
AHF (14.2%) than patients with a
pre-existing episode of AHF (10.8%)
(p = 0.0007) died. There was graded
mortality in ICU, CCU and ward
patients with mortality in ICU
patients being the highest (17.8%)
(p \ 0.0001). Conclusions: Our
data demonstrated the existence of
different subgroups based on de novo
or pre-existing episode(s) of AHF and
the site of hospitalization. Recogni-
tion of these subgroups might
improve management and outcome
by defining specific therapeutic
requirements.
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Introduction
Acute heart failure (AHF) is one of the most frequent
reasons for hospitalization in western countries. Despite
its clinical importance, AHF receives much less attention
than chronic heart failure (CHF) and has normally not
been the subject of large scale studies [1]. More recently,
the development of new therapeutic agents, such as ne-
siritide and levosimendan, has stimulated the interest in
AHF syndromes. Several epidemiological surveys in
Europe [2–5] (Zu¨rich-Helsinki; Euro Heart Survey II,
EHS II; Italian Acute Heart Failure Survey; Etude
Franc¸aise de l’Insuffisance Cardiaque Aigue the French
Study of Acute Heart Failure, EFICA) and the USA [6]
(Acute Decompensated Heart Failure National Registry,
ADHERE) provided several clues for diagnosis and
classification of these syndromes. A task force of the
European Society of Cardiology (ESC) and the European
Society of Intensive Care Medicine (ESICM) has devel-
oped guidelines for the diagnosis and treatment of AHF,
including a clinical classification based on clinical pre-
sentation [7]. In one-third of patients AHF was the first
episode of cardiac decompensation in EHFS II. These de
novo episodes of AHF have also been described to have a
worse outcome than the following episodes of AHF in
Europe [3]. The prevalence and the outcome of de novo
episodes of AHF compared with the other episodes need
to be further explored in a more global database. On the
other hand, with the exception of EFICA, in which
intensive care unit (ICU) and cardiac care unit (CCU)
patients were combined with scant details, no differenti-
ation has been done so far on AHF patients hospitalized in
ICU versus CCU and wards.
The objectives of the international Acute Heart Failure
Global Registry of Standard Treatment (ALARM-HF)
were to describe characteristics and management of hos-
pitalized AHF patients among various countries, to
compare patients with de novo AHF versus patients with
pre-existing episode(s) of AHF, and to describe subpop-
ulations hospitalized in ICU versus CCU versus ward.
Methods
Survey description
The ALARM-HF global survey collected anonymised
data from 4,953 patients in nine countries: France, Ger-
many, Italy, Spain, UK, Greece, Turkey, Australia and
Mexico. AHF was the final diagnosis for all studied
patients based on ESC/ESICM guidelines [7]. The study
was conducted as a retrospective in-hospital chart audit
survey, via questionnaire, from 666 hospitals. The hos-
pital sample was recruited to be representative according
to geographic region, hospital size (number of beds),
sector (public vs. private) and type (university vs. non-
teaching status). The study was carried out according to
the principles of the Declaration of Helsinki and approved
by all local ethics committees.
Patient inclusion
The paper-based data collection was conducted over the
period from October 2006 to March 2007. Patient care
report forms (CRFs), which included 20 discrete ques-
tions with subdivisions, were completed by the attending
physician after 5–8 consecutive AHF cases were dis-
charged, based on medical records. Patients were
classified by responsible cardiologists or ICU physicians
according to ESC/ESICM guidelines (2005) as those with
de novo (first time) AHF and those with pre-existing
episode(s) of AHF. There was no exclusion criterion.
Patient evaluation
Clinical history, signs and symptoms, and medication
(admission as well as discharge) were recorded. The pre-
hospital medical history including previous heart failure,
coronary artery disease, hypertension, diabetes, atrial
fibrillation, chronic renal disease and precipitating factors
such as acute coronary syndromes, arrhythmias, and valve
dysfunction were entered into the CRF. Details of intra-
venous drugs administered for AHF, including timing and
site of initiation, as well as dosage and duration were also
registered. Where available, echocardiography data were
collected at diagnosis and/or prior to discharge. Except
for B-type natriuretic peptide (BNP) (93.8% missing data)
and left ventricular ejection fraction (LVEF) (33.7%
missing data), missing data were very infrequent. Thus,
78.3% of the patients had complete datasets, and 96.4%
had at least 90% complete data. Patients were subclassi-
fied into three categories: those who were referred to
intensive care unit (ICU) or cardiac care unit (CCU) for at
least 24 h during hospital stay or those who were referred
only to wards and never visited ICU or CCU during
hospital stay (ward).
Statistics
The statistical analyses were conducted by the De´parte-
ment de Biostatistique et Informatique Me´dicale, Hoˆpital
Saint Louis, Paris, France.
Categorical variables are presented as counts and per-
centages, and quantitative variables as medians and
interquartile range (IQR). LVEF was an exception for
which mean and standard deviation (SD) are given. Sub-
groups of patients were compared by using chi-square tests
for categorical variables and Wilcoxon rank-sum tests for
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quantitative variables. Age categories were compared by
using the chi-square test for trends. Changes of prescription
rates between admission and discharge were assessed by
using McNemar’s test. The cumulative incidence of hos-
pital death during follow-up was estimated in a competing
risks framework, with discharge alive as the competing
event. Length of stay (LOS) for patients transferred to
another hospital or to another ward of the same hospital was
recorded at the time of transfer. Cumulative incidence
curves were compared by using Gray’s test. All tests were
two-sided, and p values less than 0.05 were considered as
indicating significant differences. Analyses were carried
out using R 2.5.1 statistical software (The R Foundation for
Statistical Computing, Vienna, Austria).
Results
Epidemiology classification
The ALARM-HF survey included a total of 4,953
patients, with a median age between 66 and 70 years for
the whole cohort, from nine countries (France 588, Ger-
many 617, Italy 679, Spain 700, UK 623, Greece 255,
Turkey 628, Mexico 601 and Australia 262), admitted to
666 hospitals of different size and type, managed by
cardiologists or intensive care physicians. The presenting
symptoms and clinical findings were dyspnoea at rest
(73%), pulmonary rales (61%), orthopnoea (56%), fatigue
(44%), peripheral oedema (43%), raised jugular venous
pressure (40%), cold extremities (26%) and weight gain
(25%) in the whole cohort.
Of the 4,953 patients, the distribution by countries is
presented in Fig. 1; as a whole, 36.2% had de novo
AHF, and 63.8% had a pre-existing episode of AHF.
Clinical presentation was decompensated congestive HF
(38.6%), pulmonary oedema (36.7%), cardiogenic shock
(11.7%), hypertensive HF (7.4%), right HF (4.5%) and
high-output HF (1.1%). The demographic characteris-
tics, comorbidities and precipitating factors are
presented in Table 1.
Patients with de novo AHF were younger and had less
comorbidities than those with a pre-existing episode of
AHF. Acute coronary syndromes were the main cause of
AHF in patients with de novo AHF, whereas arrhythmias,
infections and non-compliance to chronic medications
were the most frequent precipitating factors in patients
with pre-existing episode(s) of AHF. The mean LVEF
was 40 ± 15% in patients with de novo AHF versus
37 ± 14% in patients with a pre-existing episode of AHF
(p \ 0.0001). Systolic (SBP) and diastolic blood pressure
(DBP) at admission were lower, and pulmonary oedema
and cardiogenic shock were more frequent in patients
with de novo AHF (Table 2). Furthermore, patients pre-
senting with de novo AHF were more frequently referred
to ICU than to CCU and ward (68% vs. 42.8% vs. 48.2%,
respectively, p \ 0.0001) on admission.
Overall, 2,247 patients had been in ICU versus 1,475
patients in CCU versus 1,231 patients who had not been
either in ICU or in CCU (only wards).
ICU and CCU patients were relatively younger com-
pared with ward patients. Both hypertension and diabetes
mellitus were more frequent in ICU patients. On the other
hand, mean LVEF was 39 ± 15% in ICU patients versus
36 ± 13% in CCU patients versus 40 ± 15% in ward
patients (p \ 0.0001). Systolic (SBP) and diastolic blood
pressure (DBP) at admission were lowest, BNP levels
were the highest, and oliguria-anuria and cardiogenic
shock were most frequent in the ICU patients (Table 2).
Fig. 1 Stacked bar graph
showing distribution of six
discrete diagnoses of ESC
classification among
participating countries,
compared with Euro Heart
Survey (EHS HF II)
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Management
The site of initial management and intravenous drug
administration was the emergency room in 74%. The
remaining patients received initial treatment in the ICU in
10%, CCU in 7%, a cardiology ward in 5% and a general
medicine ward in 2%.
Details of drug treatment and other therapeutic measures
are presented in Table 3. Overall, IV diuretics were given in
89.7%, vasodilators (mainly nitroglycerine) in 41.1%, ino-
tropic agents in 39% (dobutamine 22.3%, dopamine 13%,
adrenaline and noradrenaline 7.8%, and levosimendan in
6.4%) of cases. Distribution of drug utilization among the
nine studied countries is detailed in Fig. 2.
Table 3 further shows that IV nitrate was more fre-
quently used among patients in CCU, whereas, all classes
of inotropes were most frequently utilized in patients
referred to ICU.
Other important initial non-pharmacological mea-
sures were respiratory support by CPAP in 9.6%,
mechanical ventilation in 16.2%, percutaneous coronary
intervention (PCI) 12.8%, and cardioversion 7.8% in
the whole cohort. CPAP, mechanical ventilation and
cardioversion rates were most frequent in ICU patients
(Table 3).
Outcomes
Overall hospital death rate was 12%, the majority due to
cardiogenic shock (43%). More patients with de novo
AHF (14.2%) than patients with a pre-existing episode of
AHF (10.8%) (p = 0.0007) died (Table 4).
There was graded mortality in ICU, CCU and ward
patients (Table 4 and Fig. 3). Hospital mortality in ICU
Table 1 Underlying diseases and precipitating factors of ALARM-HF patients
Characteristics Total De novo AHF p value
de novo
AHF, yes
versus no
Patients hospitalized in p values
among
ICU,
CCU,
ward
patients
Yes Nob ICU CCU Ward
Patients, n (%) 4,953 1,792 (36.2) 3,161 (63.8) 2,247 (45.4) 1,475 (29.8) 1,231 (24.8)
Age (years) \0.0001 \0.0001
\50 9.5 15.4 6.2 10.3 9.6 8.2
51–60 16.5 18.0 15.7 18.0 18.8 11.1
61–70 29.3 28.4 29.8 30.6 29.8 26.2
71–80 29.8 26.1 31.8 28.4 27.9 34.4
[80 14.9 12.1 16.5 12.7 13.9 20.1
Male gender (%) 62.4 63.6 61.7 0.19 62.4 66.9 57.0 \0.0001
Underlying diseases
Chronic systolic heart
failure (%)
36.4 2.6 55.4 \0.0001 35.8 32.1 42.5 \0.0001
Coronary artery disease (%) 30.7 25.4 33.7 \0.0001 29.4 34.2 28.8 0.002
Hypertension (%)a 70.2 66.3 72.4 \0.0001 73.2 68.1 67.3 0.00014
Diabetes (%) 45.3 38.8 49.0 \0.0001 47.9 44.1 42.2 0.003
Atrial fibrillation/flutter (%) 24.4 13.4 30.6 \0.0001 22.2 22.6 30.5 \0.0001
Chronic renal disease
(as reported) (%)
21.4 11.0 27.1 \0.0001 21.2 20.8 22.4 0.60
Anaemia (%) 14.4 8.9 17.4 \0.0001 15.7 12.4 14.2 0.024
COPD/asthma (%) 24.8 15.8 29.7 \0.0001 25.9 23.3 24.4 0.21
Pacemaker (%) 5.5 2.2 7.4 \0.0001 3.9 6.4 7.6 \0.0001
Cardiomyopathy (%) 12.6 6.2 16.3 \0.0001 11.3 13.0 14.6 0.019
Precipitating factors (on admission)
Acute coronary
syndrome (%)
36.9 48.6 30.2 \0.0001 40.9 45.9 18.8 \0.0001
Arrhythmia (%) 26.9 19.1 31.3 \0.0001 27.9 24.9 27.3 0.13
Infection (%) 16.3 12.1 18.7 \0.0001 18.9 12.1 16.7 \0.0001
Poor compliance with
medications (%)
13.4 2.2 19.7 \0.0001 10.9 12.2 19.4 \0.0001
ICU intensive care unit, CCU cardiac care unit, AHF acute heart
failure, COPD chronic obstructive pulmonary disease, ICU/CCU at
least 1 day hospital stay in ICU or CCU, ward no stay in ICU or
CCU
Exact age was not recorded, but only 5-year age categories. Median
age was between 66 and 70 years for the whole cohort, and for
patients admitted to ICU and CCU. Patients admitted to the ward
had median age between 71 and 75 years old
a Systolic blood pressure C140 mmHg or diastolic blood pressure
C90 mmHg or receiving treatment with antihypertensive
medication
b Pre-existing episode(s) of AHF
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patients was highest (17.8%), p \ 0.0001. A need for
referral to ICU seemed to impact negatively not only the
mortality but also the length of stay in the hospital
(Table 4).
Discussion
ALARM-HF is a large survey of hospitalized AHF
patients, including the identification of a large subgroup
Table 2 Hemodynamics and initial findings by de novo or pre-existing episode(s) of AHF and by ICU versus CCU versus ward
Variable De novo AHF p value Patients hospitalized in p valueb
Yes,
n = 1,792
No,
n = 3,161
ICU,
n = 2,247
CCU,
n = 1,475
Ward,
n = 1,231
Median SBP (mmHg) (IQR) 130 (95–160) 130 (103–160) \0.0001 120 (95–160) 130 (100–160) 140 (110–160) \0.0001
SBP \ 100 (mmHg),
no. (%)
466 (26.3) 549 (17.5) \0.0001 617 (27.7) 298 (20.3) 100 (8.3) \0.0001
Median DBP (mmHg) (IQR) 75 (60–90) 80 (60–95) \0.0001 78 (58–95) 80 (60–94) 80 (70–95) \0.0001
Heart rate, median (IQR) 110 (90–122) 107 (90–120) 0.002 110 (90–125) 110 (90–120) 100 (86–118) \0.0001
Cardiogenic shock (%) 19.1 7.5 \0.0001 16.2 12.3 2.9 \0.0001
Pulmonary edema (%) 39.8 35.0 0.0008 38.1 42.8 27.0 \0.0001
Cold extremities (%) 29.3 24.3 0.0001 33.1 26.2 13.2 \0.0001
Normal diuresis at baseline
(%)
55.2 52.6 0.093 47.2 54.3 65.5 \0.0001
Median BNP (IQR)a 908
(415–1,572)
1,040
(576–2,212)
0.020 1108
(552–1,995)
1045
(642–2,136)
700
(313–1,640)
0.009
SBP systolic blood pressure, DBP diastolic blood pressure
a BNP recorded in 307 patients
b p among ICU versus CCU versus ward
Table 3 Treatment during hospitalization ICU versus CCU versus ward
Treatment performed Patients hospitalized in p value
All, n = 4,953
(%)
ICU, n = 2,247
(%)
CCU, n = 1,475
(%)
Ward, n = 1,231
(%)
CPAP 9.6 15.8 6.3 2.2 \0.0001
Mechanical ventilation 16.2 30.0 6.8 2.3 \0.0001
Oral diuretic 60.5 49.1 65.7 75.0 \0.0001
IV diuretic 89.7 89.9 90.3 88.5 0.30
Oral spironolactone/eplerenone 27.5 23.4 28.6 33.7 \0.0001
IV nitrate 41.1 44.0 48.5 27.2 \0.0001
Beta-blocker 37.8 30.7 45.2 42.1 \0.0001
IV inotrope
Adrenaline 3.6 6.6 1.5 0.7 \0.0001
Dobutamine 22.3 30.3 21.8 8.2 \0.0001
Dopamine 13.0 16.0 14.2 6.1 \0.0001
Levosimendan 6.4 7.7 7.3 3.1 \0.0001
Noradrenaline 4.2 8.2 1.3 0.2 \0.0001
Amiodarone 2.6 3.2 2.6 1.7 0.037
Heparin (UFH) 2.0 3.1 1.7 0.2 \0.0001
LMWH 1.0 1.5 0.5 0.8 0.0089
PCI 12.8 13.4 19.1 4.1 \0.0001
CABG 3.0 4.5 2.6 0.7 \0.0001
IABP 4.8 6.1 6.6 0.4 \0.0001
Pacemaker 2.5 3.2 2.4 1.1 0.00085
ICD 1.7 1.2 2.5 1.6 0.0071
Valvular surgery 3.5 5.2 2.5 1.5 \0.0001
Cardioversion 7.8 9.5 6.4 6.3 0.0003
CPAP continuous positive airway pressure, UFH infractionated
heparin, LMWH low molecular weight heparin, PCI percutaneous
coronary intervention, CABG coronary artery bypass grafting, ICD
implantable cardioverter defibrillator, IABP intraaortic balloon
counterpulsation
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of de novo AHF patients, and a detailed documentation of
the site and mode of treatment in ICU, CCU and wards,
respectively. ALARM-HF showed that the first episode of
AHF was more severe with a worse outcome than the
following episodes of AHF. In addition, there was a
graded severity in patients hospitalized in ICU versus
CCU and ward.
The total in-hospital mortality of ALARM (12%) was
higher than the Italian survey (7.3%), EHFS II (6.7%) and
ADHERE (4%) and lower than EFICA (27%) [3–5, 6].
Those differences are driven by many factors including
the incidence of 11.7% of cardiogenic shock in the
present cohort and the severity of ALARM patients as
seen by high prevalence of patients hospitalized in ICU
and CCU.
In most surveys and trials dealing with AHF, no dis-
tinction was made between the first episode (de novo) and
the following episodes of AHF [2, 4, 10]. ALARM-HF
confirms that an AHF episode was more deadly when it
occurred for the first time (14 vs. 10% in de novo AHF
and AHF with pre-existing episodes). Our study further
describes important clinical differences between the two
groups of patients including a lower systolic blood pres-
sure at admission and a higher incidence of acute
coronary syndrome as a precipitating factor (48.6 vs.
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Fig. 2 Bar graph showing
treatment strategies, namely
intravenous diuretics,
intravenous vasodilators and
inotropes, among participating
countries
Table 4 Outcomes and length of stay in ALARM-HF study
Total,
n = 4,953
De novo AHF Patients hospitalized in p valuea
Yes,
n = 1,792
No,
n = 3,161
ICU,
n = 2,247
CCU,
n = 1,475
Ward,
n = 1,231
Outcome no.
Transfer 752 360 392 486 203 63
Death 529 221 308 334 141 54
Discharge 3,672 1,211 2,461 1,427 1,131 1,114
LOS (days), median (IQR) 6 (4–10) 6 (4–10) 7 (4–10) 7 (4–11) 6 (4–9) 6 (4–9) \0.0001
Hospital mortality at 24 h, (%) 3.5 4.2 3.1 4.0 3.9 2.1 0.80
Overall hospital mortality, (%) 12.0 14.2 10.8 17.8 10.5 4.5 \0.0001
ICU/CCU stay (days), median (IQR) 3 (2–6) 3 (2–6) 3 (2–6) 4 (2–6) 3 (2–5) –
LOS is reported for all patients (including in-hospital deaths and transfers). LOS in ICU/CCU for patients admitted to these units
a p for ICU versus CCU versus ward
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Fig. 3 In-hospital mortality in patients hospitalized in ICU or CCU for
at least 24 h and in the ward without stay in either ICU or CCU (ward)
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30.2% in de novo AHF and in AHF with pre-existing
episodes) that both could possibly influence for worse
outcomes among patients with de novo AHF [8]. Some
other hypotheses can also be raised regarding the greater
severity of the first AHF episode. This includes the acti-
vation of different pathways, such as the extent of
sympathetic nervous system activation, that may be dif-
ferent in patients with de novo AHF and in patients with a
pre-existing episode of AHF. Paradoxically, a lower
mortality of AHF was observed in patients with pre-
existing CHF despite a more frequent history of atrial
fibrillation and of arrhythmia as precipitating factors, as
well as more frequent renal disease and more frequent
comorbidities, including COPD. On the other hand,
patients with a pre-existing episode of AHF received
medications before admission that might have altered the
severity of the AHF episode. Accordingly, ALARM-HF
emphasizes the need to stratify AHF in future surveys and
trials as de novo AHF and AHF with pre-existing epi-
sodes. Indeed, a new treatment might be more effective in
one of the two categories of AHF episode.
Presentation of figures comparing ICU versus CCU
versus ward is one of the unique features of the present
manuscript. With the exception of ADHERE [6], which
combined ICU/CCU, graded severity and mortality was
presented for the first time. In the present study, ALARM
shows that patients admitted to the ICU had more hyper-
tension and diabetes as underlying diseases and presented
with more cardiogenic shock, lower systolic and diastolic
blood pressure, more frequent oliguria-anuria and periph-
eral hypoperfusion than the other AHF patients. Although
not recorded, severity scores are very likely worse in
patients admitted to ICU. Poor hemodynamic profile yiel-
ded longer LOS for patients in ICU compared with CCU or
ward. Besides, all kinds of inotropes were more frequently
utilized in the ICU patients. Despite extensive utilization of
many therapies, mortality was tripled among patients
referred to ICU compared with ward patients, and of note, it
was higher in ICU compared with CCU.
On the other hand, patients referred to CCU presented
with a higher rate of pulmonary edema, more frequent
history of coronary artery disease, more frequent pre-
sentation with acute coronary syndrome, more frequent
use of beta-blockers and nitrates, and more frequent
percutaneous intervention at index hospitalization com-
pared with ICU or ward patients.
Therapeutic measures were evaluated in detail not
only for the total population, as usually reported in most
AHF surveys, but also for the first time in the different
subgroups of patients including those in ICU. As expec-
ted, IV diuretics remained the most frequently utilized
drugs for initial symptomatic treatment in all forms of
AHF, followed by nitrates as vasodilators. Inotropes were
also often administered in all participating countries to
26–51% of patients, despite a prevailing negative car-
diologic opinion based on reports indicating possible
adverse outcomes with frequently used drugs, such as
dobutamine and milrinone [9, 10]. CPAP was used in
9.6% of studied patients and 16% required mechanical
ventilation. The lower than expected prevalence of CPAP
might be related to the fact that many centres in Europe
do not utilize CPAP either because of lack of frequent
practice and/or availability or to the severity of the
patients that needed mechanical ventilation rather than
CPAP. Of note, in the present survey, close to 50% of the
ICU patients needed CPAP or mechanical ventilation.
Limitations of the ALARM-HF survey
Data collection in the participating hospitals was limited
to 5–8 consecutive hospital discharges with a clinical
diagnosis of AHF according to the ESC/ESICM classifi-
cation of 2005. We note that there was a vast range in
terms of organisation and quality of patient care. There-
fore, we cannot assure that the cases included represent
the overall AHF patient population in all countries. A
diagnostic criterion was probably not always uniformly
applied by all involved cardiologists and intensive care
specialists. However, final adjudication to AHF subgroups
was based on the completed data in the case reports which
were compiled following discharge.
Indeed, our survey did not allow one to differentiate
overlapping clinical characteristics, as in the case of
pulmonary oedema between acute decompensated HF
and hypertensive HF. Pulmonary oedema (PE) was
actually a very frequent diagnosis, indicated by physi-
cians in charge in 37% of our studied patients. Of note,
PE was also an initial diagnosis in 49.6% in the Italian
AHF survey [3]. Although the definition of PE is
accepted worldwide, regional interpretations are indeed
possible. We know that physicians could only quote
one of the six items of the ESC classification. Very
likely, patients with PE were derived from those with
hypertensive HF and as well as those with pre-existing
chronic systolic heart failure and our survey did not
allow differentiation of either. This shows some of the
limits of ESC/ESICM classification.
Another limitation is that the analysis of drug uti-
lization and other therapeutic interventions relied on the
case report forms without the possibility to compare the
data with routine management guidelines in these hos-
pitals. Therefore, our findings might be questioned with
regards to representing established clinical practice.
Long-term outcome data are also lacking. Because of
the design of the ALARM-HF registry, which was
based on anonymised data, a follow-up after hospital
discharge was not possible.
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Conclusion
Using pre-defined criteria, we compared initial findings,
treatments and outcomes in a broad range of hospital
settings in various regions of the world. Results of
ALARM-HF designate that there are further distinct
subgroups of patients beyond ESC/ESICM classification
with graded severity of AHF. On the basis of the
results derived from ALARM-HF, we conclude that the
first episode of AHF is more deadly, and for the first
time in the literature to the best of our knowledge, ICU
patients differ from CCU and ward patients by having
not only the poorest hemodynamics but also the worst
prognosis. Those parameters should help in the future
stratification of patients for well-designed prospective
randomized trials so that future progress in this difficult
field occurs.
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